131 related articles for article (PubMed ID: 32211672)
1. Urine metallomics signature as an indicator of pancreatic cancer.
Schilling K; Larner F; Saad A; Roberts R; Kocher HM; Blyuss O; Halliday AN; Crnogorac-Jurcevic T
Metallomics; 2020 May; 12(5):752-757. PubMed ID: 32211672
[TBL] [Abstract][Full Text] [Related]
2. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
[TBL] [Abstract][Full Text] [Related]
3. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
[TBL] [Abstract][Full Text] [Related]
4. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.
Roy R; Zurakowski D; Wischhusen J; Frauenhoffer C; Hooshmand S; Kulke M; Moses MA
Br J Cancer; 2014 Oct; 111(9):1772-9. PubMed ID: 25137018
[TBL] [Abstract][Full Text] [Related]
5. Urinary metabolite prognostic biomarker panel for pancreatic ductal adenocarcinomas.
Hipperson L; Hadden WJ; Nahm CB; Gill AJ; Samra JS; Dona A; Mittal A; Sahni S
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129966. PubMed ID: 34329704
[TBL] [Abstract][Full Text] [Related]
6. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients.
Blyuss O; Zaikin A; Cherepanova V; Munblit D; Kiseleva EM; Prytomanova OM; Duffy SW; Crnogorac-Jurcevic T
Br J Cancer; 2020 Mar; 122(5):692-696. PubMed ID: 31857725
[TBL] [Abstract][Full Text] [Related]
7. Zinc stable isotopes in urine as diagnostic for cancer of secretory organs.
Schilling K; Moore RET; Sullivan KV; Capper MS; Rehkämper M; Goddard K; Ion C; Coombes RC; Vesty-Edwards L; Lamb AD; Halliday AN; Larner F
Metallomics; 2021 May; 13(5):. PubMed ID: 33877364
[TBL] [Abstract][Full Text] [Related]
8. Serum and tissue metallome of pancreatic ductal adenocarcinoma.
Byeon S; du Toit-Thompson T; Hipperson L; Maloney S; Wenzel R; Gill AJ; Samra JS; Mittal A; Sahni S
Cancer Sci; 2024 May; 115(5):1446-1458. PubMed ID: 38438247
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine.
Arasaradnam RP; Wicaksono A; O'Brien H; Kocher HM; Covington JA; Crnogorac-Jurcevic T
Gastroenterology; 2018 Feb; 154(3):485-487.e1. PubMed ID: 29129714
[No Abstract] [Full Text] [Related]
10. Nano-biotinylated liposome-based immunoassay for the ultrasensitive detection of protein biomarker in urine.
Liu P; Fang X; Cao H; Gu M; Kong J; Deng A
Talanta; 2018 Mar; 179():472-477. PubMed ID: 29310262
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
12. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
[TBL] [Abstract][Full Text] [Related]
13. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?
Yip-Schneider MT; Soufi M; Carr RA; Flick KF; Wu H; Colgate CL; Schmidt CM
Am J Surg; 2020 Mar; 219(3):492-495. PubMed ID: 31554598
[TBL] [Abstract][Full Text] [Related]
14. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
15. Urine test can detect early stage pancreatic cancer.
Bagcchi S
Lancet Oncol; 2015 Sep; 16(9):e431. PubMed ID: 26256762
[No Abstract] [Full Text] [Related]
16. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
17. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution.
Napoli C; Sperandio N; Lawlor RT; Scarpa A; Molinari H; Assfalg M
J Proteome Res; 2012 Feb; 11(2):1274-83. PubMed ID: 22066465
[TBL] [Abstract][Full Text] [Related]
18. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
19. Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma.
Igbinigie E; Guo F; Jiang SW; Kelley C; Li J
Clin Chim Acta; 2019 Jan; 488():226-234. PubMed ID: 30452897
[TBL] [Abstract][Full Text] [Related]
20. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
Yu S; Li Y; Liao Z; Wang Z; Wang Z; Li Y; Qian L; Zhao J; Zong H; Kang B; Zou WB; Chen K; He X; Meng Z; Chen Z; Huang S; Wang P
Gut; 2020 Mar; 69(3):540-550. PubMed ID: 31562239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
